Lexeo Therapeutics Inc
Research Lexeo Therapeutics Inc (LXEO) on Bullrun: market cap USD 239.01M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLXEO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 239.01M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 25.87M
- Free cash flow-USD 17.60M
Valuation Snapshot
latest market cap is USD 239.01M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 100.00M | -USD 98.96M | n/a | -1.86 | USD 63.00M | USD 7.89M | USD 246.67M |
| FY2024 | USD 0 | -USD 98.33M | -USD 81.63M | n/a | -3.09 | USD 35.01M | USD 9.92M | USD 116.84M |
| FY2023 | USD 0 | -USD 66.39M | -USD 59.61M | n/a | -12.4 | USD 121.47M | USD 11.64M | USD 113.54M |
| FY2022 | USD 654.00K | -USD 59.28M | -USD 55.23M | n/a | -36.36 | USD 77.34M | USD 13.48M | -USD 112.95M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 239.01M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 724.87M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 217.64M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 357.58M | n/a | n/a | n/a |
About Lexeo Therapeutics Inc
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Lexeo Therapeutics Inc's market cap?
Lexeo Therapeutics Inc's market capitalization is USD 239.01M.
What does Lexeo Therapeutics Inc do?
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.